Clinical trials: Pigmented Villonodular Synovitis
Pigmented Villonodular Synovitis, Diffuse-type Giant Cell Tumor
Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor
Nilotinib is a drug that is used to treat a form of a blood cancer called leukemia. Nilotinib works by blocking the action of a protein that might be important for the growth of pigmented villonodular synovitis (PVNS).
- Conditions
- Pigmented Villonodular Synovitis, Diffuse-type Giant Cell Tumor, Tenosynovial Giant Cell Tumor
- Trial name
- NCT01207492
- Testing
- nilotinib
- Where
- 7 sites in United States
- Volunteers
- 17 people
- Sponsor
- Andrew J. Wagner, MD, PhD
Pigmented Villonodular Synovitis
Screening of Specific Genes for Pigmented Villous Nodular Synovitis
This study retrospectively analyzed the history of present illness of PVNS patients in our hospital. The enrolled patients were followed up by telephone to follow up their postoperative recovery and living conditions.
- Trial name
- NCT04955535
- Testing
- Arthroscopic synovectomy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University Third Hospital
TGCT
Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)
This is a multicenter, Phase 3, randomised, double-blind, placebo-controlled study, which aims to evaluate the efficacy and safety of the investigational drug emactuzumab for the treatment of patients with localized or diffuse…
- Trial name
- TANGENT (NCT05417789)
- Testing
- Emactuzumab
- Where
- 33 sites in United States, Belgium and 10 more
- Volunteers
- 128 people
- Sponsor
- SynOx Therapeutics Limited
Pigmented Villonodular Synovitis
Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT)
The purpose of this study is to explore the efficacy of nilotinib as a treatment of patients with progressive or relapsing pigmented villo-nodular synovitis / tenosynovial giant cell tumour (PVNS/TGCT) who cannot be treated by…
- Trial name
- NCT01261429
- Testing
- Tasigna
- Where
- 15 sites in France, Italy and 3 more
- Volunteers
- 50 people
- Sponsor
- Centre Leon Berard
Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis (PVNS)
An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee
AMB-051-01 is a multicenter study with an adaptive design that will enroll subjects with Tenosynovial Giant Cell Tumor (TGCT) of the knee for 12 weeks of multiple-dose, open-label treatment with intra-articular AMB-05X.
- Trial name
- NCT04731675
- Testing
- AMB-05X
- Where
- 6 sites in United States, Netherlands and 2 more
- Volunteers
- 11 people
- Sponsor
- AmMax Bio, Inc.
Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis
Study of Vimseltinib for Tenosynovial Giant Cell Tumor
This is a multicenter Phase 3 clinical study, which aims to evaluate the effectiveness of an investigational drug called vimseltinib for the treatment of tenosynovial giant cell tumor (TGCT) in cases where surgical removal of the…
- Conditions
- Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor, Diffuse
- Trial name
- MOTION (NCT05059262)
- Testing
- Vimseltinib
- Where
- 35 sites in United States, Australia and 11 more
- Volunteers
- 123 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Tenosynovial Giant Cell Tumor
A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan
This phase 2, multicenter, two-part, open-label, single-arm study will be conducted in Japan and will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of pexidartinib in adult participants with symptomatic…
- Trial name
- NCT04703322
- Testing
- Pexidartinib
- Where
- 6 sites in Japan
- Volunteers
- 9 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Tenosynovial Giant Cell Tumor
Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)
The primary purpose of this study is to assess the tolerability, pharmacokinetics, and efficacy of pimicotinib in Japanese participants with TGCT
- Trial name
- NCT07499362
- Testing
- Pimicotinib
- Where
- 4 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Advanced Malignant Neoplasm, Pigmented Villonodular Synovitis
Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
This is a multicenter, open-label Phase 1/2 study of vimseltinib in patients with malignant solid tumors and tenosynovial giant cell tumor (TGCT).
- Conditions
- Advanced Malignant Neoplasm, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor
- Trial name
- NCT03069469
- Testing
- Vimseltinib
- Where
- 24 sites in United States, Australia and 7 more
- Volunteers
- 120 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Advanced Malignant Solid Tumors, TGCT
Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT
To evaluate the safety and tolerability of HMPL-653 in patients with advanced solid tumors who have failure of standard of care or can not tolerate standard of care or those with TGCT, and to determine the maximum tolerated dose…
- Trial name
- NCT05277454
- Testing
- HMPL-653
- Where
- 5 sites in China
- Volunteers
- 113 people
- Sponsor
- Hutchison Medipharma Limited
Hepatotoxicity, Tenosynovial Giant Cell Tumor
A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment
A study to evaluate the long-term risk of hepatic failure with TURALIO™ (pexidartinib) and the mechanism of liver injury based upon optional liver biopsy information among patients who received or are receiving TURALIO™…
- Trial name
- NCT04635111
- Testing
- TURALIO™
- Where
- 6 sites in United States
- Sponsor
- Daiichi Sankyo
Pigmented Villonodular Synovitis, Giant Cell Tumors of the Tendon Sheath
Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)
This is a Phase 3 clinical study, which aims to evaluate the effectiveness of an investigational drug called pexidartinib for the treatment of certain tumors for which surgical removal could cause more harm than good.
- Conditions
- Pigmented Villonodular Synovitis, Giant Cell Tumors of the Tendon Sheath, Tenosynovial Giant Cell Tumor
- Trial name
- ENLIVEN (NCT02371369)
- Testing
- Pexidartinib
- Where
- 39 sites in United States, Australia and 10 more
- Volunteers
- 120 people
- Sponsor
- Daiichi Sankyo
Adipocytic Neoplasm, Liposarcoma
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
The study participant has been diagnosed with non-rhabdomyosarcoma (NRSTS). Primary Objectives Intermediate-Risk To estimate the 3-year event-free survival for intermediate-risk patients treated with ifosfamide, doxorubicin…
- Conditions
- Adipocytic Neoplasm, Liposarcoma, Atypical Fibroxanthoma, Angiomatoid Fibrous Histiocytoma
- Trial name
- NCT06239272
- Testing
- Surgical resection, Proton beam radiation therapy, Pazopanib
- Where
- 7 sites in United States
- Volunteers
- 139 people
- Sponsor
- St. Jude Children's Research Hospital
Tenosynovial Giant Cell Tumor
Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib
This study is designed to evaluate the discontinuation/re-treatment of pexidartinib therapy in previously treated participants with tenosynovial giant cell tumor (TGCT).
- Trial name
- PLX3397 (NCT04526704)
- Testing
- Pexidartinib
- Where
- 16 sites in United States, Australia and 5 more
- Volunteers
- 32 people
- Sponsor
- Daiichi Sankyo
Tenosynovial Giant Cell Tumor, Diffuse
Neoadjuvant Pimicotinib Combined With Surgery Versus Upfront Surgery for Diffuse Tenosynovial Giant Cell Tumor
Tenosynovial giant cell tumor (TGCT) is a rare neoplasm predominantly occurring in young and middle-aged adults, characterized by high recurrence and high disability rates. Surgery represents the first-line treatment at present.
- Trial name
- NEXPERT (NCT07707882)
- Testing
- Pimicotinib, Tumor resection surgery
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Tenosynovial Giant Cell Tumor
A Study of DCC-3014 to Evaluate the Efficacy, Safety, and Pharmacokinetics in Subjects With TGCT
To evaluate the efficacy, safety, and pharmacokinetics of DCC-3014 in subjects with Tenosynovial Giant Cell Tumor
- Trial name
- NCT07832747
- Testing
- DCC-3014
- Where
- Japan
- Volunteers
- 18 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Synovial Diseases, Pigmented Villonodular Synovitis
Clinical Study of Magnetic Resonance Imaging and Deep Learning of Joint Synovial Disease
Through the high-throughput feature extraction of magnetic resonance images, the deep learning prediction model of joint synovial lesions is constructed used for the diagnosis, differential diagnosis and curative effect…
- Conditions
- Synovial Diseases, Pigmented Villonodular Synovitis, Gout, Rheumatoid Arthritis
- Trial name
- NCT04952896
- Testing
- Synovitis diagnosis
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Peking University Third Hospital
Tenosynovial Giant Cell Tumor
MOVE: Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib
The goal of this observational study is to better understand real-world use of vimseltinib, treatment patterns, and health-related quality of life in participants treated with vimseltinib for TGCT.
- Trial name
- MOVE (NCT07075471)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Giant Cell Tumors
Tenosynovial Giant Cell Tumors (TGCT) Observational Platform Project
TGCT is a rare disease that is difficult to manage, surgical resection is the primary treatment currently available. To date no disease registry exists and there is little data available detailing the management of patients with…
- Trial name
- TOP (NCT02948088)
- Where
- 15 sites in United States, Austria and 6 more
- Volunteers
- 183 people
- Sponsor
- Daiichi Sankyo
Neurofibroma, Plexiform, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
Background: Some people with cancer have solid tumors. Others have refractory leukemia. This may not go away after treatment. Researchers want to see if a drug called TURALIO(R) can shrink tumors or stop them from growing.
- Conditions
- Neurofibroma, Plexiform, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Promyelocytic, Acute, Sarcoma
- Trial name
- NCT02390752
- Testing
- TURALIO(R)
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)